Amedeo Smart

Free Medical Literature Service


 

Amedeo

Multiple Sclerosis

  Free Subscription

Articles published in
Neurology
    June 2024
  1. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    >> Share

  2. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    >> Share

    May 2024
  3. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    >> Share

  4. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    >> Share

  5. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    >> Share

  6. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    >> Share

  7. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    >> Share

    April 2024

  8. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    >> Share

  9. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    >> Share

  10. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    >> Share

    March 2024
  11. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    >> Share

  12. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    >> Share


  13. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    >> Share

  14. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    >> Share

  15. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    >> Share

  16. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    >> Share

  17. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    >> Share

  18. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    >> Share

  19. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    >> Share

    February 2024
  20. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    >> Share

  21. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    >> Share

  22. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    >> Share

  23. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    >> Share

    January 2024
  24. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    >> Share

  25. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    >> Share

  26. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    >> Share

  27. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    >> Share

  28. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    >> Share

  29. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    >> Share

  30. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    >> Share

    December 2023
  31. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    >> Share

  32. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    >> Share

    October 2023
  33. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    >> Share

    September 2023
  34. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    >> Share

  35. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    >> Share

  36. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    >> Share

  37. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    >> Share

  38. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    >> Share

  39. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    >> Share

    August 2023
  40. BSTEH G, Hegen H, Altmann P, Auer M, et al
    Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.
    Neurology. 2023;101:e784-e793.
    >> Share

  41. GRAVES JS
    Cell Specific Aging in Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207679.
    >> Share

  42. MALTBY V, Xavier A, Ewing E, Campagna MP, et al
    Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis.
    Neurology. 2023 Aug 4:10.1212/WNL.0000000000207489.
    >> Share

    July 2023
  43. FADDA G, Cardenas de la Parra A, O'Mahony J, Waters P, et al
    Deviation From Normative Whole Brain and Deep Gray Matter Growth in Children With MOGAD, MS, and Monophasic Seronegative Demyelination.
    Neurology. 2023;101:e425-e437.
    >> Share

  44. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    >> Share

  45. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    >> Share

  46. LONGBRAKE E, Kalincik T
    Early Treatment for Multiple Sclerosis: Time Is Brain.
    Neurology. 2023 Jul 19:10.1212/WNL.0000000000207754.
    >> Share

  47. EHRHARDT H, Lambe J, Moussa H, Vasileiou ES, et al
    Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post-Hoc Analyses of the SPRINT-MS Trial.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207551.
    >> Share

  48. BENNETT JL
    Sprinting to the Finish: Optical Coherence Tomography, Retinal Atrophy, and Neurodegeneration in Progressive Multiple Sclerosis.
    Neurology. 2023 Jul 17:10.1212/WNL.0000000000207607.
    >> Share

  49. JAIN A, Arena VP, Steigerwald C, Borja MJ, et al
    Pearls and Oy-sters: CSF1R-Related Leukoencephalopathy With Spinal Cord Lesions Mimicking Multiple Sclerosis.
    Neurology. 2023 Jul 5:10.1212/WNL.0000000000207502.
    >> Share

  50. TOOSY AT, Vidal-Jordana A
    Is the Optic Nerve Overdue as a Criterion to Support the Diagnosis of Multiple Sclerosis?
    Neurology. 2023 Jul 3:10.1212/WNL.0000000000207625.
    >> Share

    June 2023
  51. KOCH-HENRIKSEN N
    Worldwide Disparity in the Effectiveness of the Diagnostic Process in Multiple Sclerosis.
    Neurology. 2023 Jun 30:10.1212/WNL.0000000000207530.
    >> Share

  52. SOLOMON AJ, Marrie RA, Viswanathan S, Correale J, et al
    Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third Edition.
    Neurology. 2023 Jun 15:10.1212/WNL.0000000000207481.
    >> Share

  53. ROTSTEIN D, Schneider R
    A Birth Year Cohort and What It Can Reveal About Lipid Mediators as Putative Biomarkers of Progression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207605.
    >> Share

  54. BROOS JY, Loonstra FC, de Ruiter LRJ, Gouda MMTEE, et al
    Association of Arachidonic Acid-Derived Lipid Mediators With Disease Severity in Patients With Relapsing and Progressive Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207459.
    >> Share

  55. KOWALEC K, Fitzgerald KC, Salter A, Dolovich C, et al
    Polygenicity of Comorbid Depression in Multiple Sclerosis.
    Neurology. 2023 Jun 8:10.1212/WNL.0000000000207457.
    >> Share

    April 2023
  56. LUSK JB, Hoffman MN, Clark AG, Bae J, et al
    Association Between Neighborhood Socioeconomic Status and 30-Day Mortality and Readmission for Patients With Common Neurologic Conditions.
    Neurology. 2023;100:e1776-e1786.
    >> Share

  57. LEAVITT VM
    The Mismeasure of Change: Better Cognitive Measurement Instruments are Urgently Needed for Multiple Sclerosis Research.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207431.
    >> Share

  58. CASTROGIOVANNI N, Mostert J, Repovic P, Bowen JD, et al
    Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
    Neurology. 2023 Apr 18:10.1212/WNL.0000000000207301.
    >> Share

    March 2023
  59. CARTA S, Cobo Calvo A, Armangue T, Saiz A, et al
    Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
    Neurology. 2023;100:e1095-e1108.
    >> Share

    January 2023
  60. PATIL SA, Grossman S, Kenney R, Balcer LJ, et al
    Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture.
    Neurology. 2023;100:244-253.
    >> Share

  61. CACCIAGUERRA L, Morris P, Tobin WO, Chen JJ, et al
    Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2023 Jan 23:10.1212/WNL.0000000000206820.
    >> Share

  62. HORTON MK, Robinson SC, Shao X, Quach H, et al
    A Cross-Trait, Mendelian Randomization Study to Investigate Whether Migraine Is a Risk Factor for Multiple Sclerosis.
    Neurology. 2023 Jan 11:10.1212/WNL.0000000000206791.
    >> Share

    December 2022
  63. BORDEA E, Hunter RM
    Excess Treatment Costs of Multiple Sclerosis: What Can We Learn From Longitudinal Population-Based Data?
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206804.
    >> Share

  64. GAVOILLE A, Rollot F, Casey R, Debouverie M, et al
    Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
    Neurology. 2022 Dec 23:10.1212/WNL.0000000000206774.
    >> Share

  65. BERGSLAND N, Dwyer MG, Jakimovski D, Tavazzi E, et al
    Association of Choroid Plexus Inflammation on MRI With Clinical Disability Progression Over 5 Years in Patients With Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000201608.
    >> Share

  66. BOFFA G, Signori A, Massacesi L, Mariottini A, et al
    Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206750.
    >> Share

  67. MULLER J, Noteboom S, Granziera C, Schoonheim MM, et al
    Understanding the Role of the Choroid Plexus in Multiple Sclerosis as an MRI Biomarker of Disease Activity.
    Neurology. 2022 Dec 21:10.1212/WNL.0000000000206806.
    >> Share

  68. MULLER-JENSEN L, Kriedemann H, Anvari K, Huehnchen P, et al
    Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Neurology. 2022 Dec 20:10.1212/WNL.0000000000206743.
    >> Share

    November 2022
  69. KHAKBAN A, Llorian ER, Michaux KD, Patten SB, et al
    Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study From 2001 to 2020 in British Columbia, Canada.
    Neurology. 2022 Nov 30:10.1212/WNL.0000000000201645.
    >> Share

  70. ZIEMSSEN T
    Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:868.
    >> Share

  71. PARNETTI L, Gaetani L
    Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use.
    Neurology. 2022;99:869.
    >> Share

  72. LEWIS A, Galetta S
    Editors' Note: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818.
    >> Share

  73. BEBO BF
    Author Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:819.
    >> Share

  74. VARGAS WS
    Reader Response: The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022;99:818-819.
    >> Share

    October 2022
  75. LI L, Avina-Zubieta JA, Bernstein CN, Kaplan GG, et al
    Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor Alpha in Four Canadian Provinces: A Population-Based Study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201472.
    >> Share


  76. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201391.
    >> Share

  77. STRIJBIS EMM, Koch MW
    TNF Alfa Blockers and the Risk of Multiple Sclerosis.
    Neurology. 2022 Oct 28. pii: WNL.0000000000201629.
    >> Share

  78. DOBSON R, Bove R
    In Vitro Fertilization and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022;99:737-738.
    >> Share

  79. SNETSELAAR L, Cheek JJ, Fox SS, Healy HS, et al
    Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201371.
    >> Share

  80. SPAIN R, Piccio L, Langer-Gould AM
    The Role of Diet in Multiple Sclerosis: Food for Thought.
    Neurology. 2022 Oct 18. pii: WNL.0000000000201565.
    >> Share

  81. DUBESSY AL, Stankoff B, Arnulf I
    Author Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:727.
    >> Share

  82. SIEGLER JE, Galetta S
    Editors' Note: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726.
    >> Share

  83. SPARASCI D, Zecca C, Gobbi C, Manconi M, et al
    Reader Response: Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2022;99:726-727.
    >> Share

  84. MURPHY OC, Calabresi PA, Gold DR
    Teaching Video NeuroImage: Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis.
    Neurology. 2022 Oct 11. pii: WNL.0000000000201452.
    >> Share

  85. GANESH A, Galetta S
    Editors' Note: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630.
    >> Share

  86. BARRO C
    Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:630-631.
    >> Share

  87. LEPPERT D, Kropshofer H, Haring D, Dahlke F, et al
    Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022;99:631.
    >> Share

  88. CORTESE R, Carrasco FP, Tur C, Bianchi A, et al
    Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging.
    Neurology. 2022 Oct 3. pii: WNL.0000000000201465.
    >> Share

    September 2022
  89. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    >> Share

  90. CAROTENUTO A, Valsasina P, Schoonheim MM, Geurts JJ, et al
    Investigating Functional Network Abnormalities and Associations With Disability in Multiple Sclerosis.
    Neurology. 2022 Sep 12. pii: WNL.0000000000201264.
    >> Share

    August 2022
  91. CORDANO C, Nourbakhsh B, Yiu HH, Papinutto N, et al
    Differences in Age-Related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.
    Neurology. 2022 Aug 29. pii: WNL.0000000000200977.
    >> Share

  92. VILLOSLADA P, Llufriu S
    Preventing Neurodegeneration in Multiple Sclerosis Is Required From the Earliest Stages of the Disease.
    Neurology. 2022 Aug 29. pii: WNL.0000000000201223.
    >> Share

  93. HWANG S, Garcia-Dominguez MA, Fitzgerald KC, Saylor DR, et al
    Association of Multiple Sclerosis Prevalence With Sociodemographic, Health Systems, and Lifestyle Factors on a National and Regional Level.
    Neurology. 2022 Aug 24. pii: WNL.0000000000200962.
    >> Share

  94. BRENTON JN, Florenzo B, Koshiya H, Min S, et al
    Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2022 Aug 19. pii: WNL.0000000000201098.
    >> Share

  95. ROOS I, Malpas C, Leray E, Casey R, et al
    Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022 Aug 17. pii: WNL.0000000000201029.
    >> Share

  96. DOBSON R, Bove R
    IVF and Multiple Sclerosis: Evolving Treatments and Reducing Relapse Risk.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201242.
    >> Share

  97. MAINGUY M, Tillaut H, Degremont A, Le Page E, et al
    Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple Sclerosis.
    Neurology. 2022 Aug 11. pii: WNL.0000000000201027.
    >> Share

  98. O'MAHONY J, Salter A, Ciftci B, Fox RJ, et al
    Physical and Mental Health-Related Quality of Life Trajectories Among People With Multiple Sclerosis.
    Neurology. 2022 Aug 10. pii: WNL.0000000000200931.
    >> Share

  99. BSTEH G, Krajnc N, Riedl K, Altmann P, et al
    Retinal Layer Thinning After Optic Neuritis is Associated With Future Relapse Remission in Relapsing Multiple Sclerosis.
    Neurology. 2022 Aug 2. pii: WNL.0000000000200970.
    >> Share

    June 2022
  100. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    >> Share

  101. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    >> Share

  102. FREEDMAN MS, Pozzilli C, Havrdova EK, Lemle A, et al
    Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.
    Neurology. 2022 Jun 6. pii: WNL.0000000000200606.
    >> Share

    May 2022
  103. SOTIRCHOS ES, Vasileiou ES, Filippatou AG, Fitzgerald KC, et al
    Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Neurology. 2022 May 26. pii: WNL.0000000000200778.
    >> Share

  104. GRAVES J
    Identifying Multiple Sclerosis Activity: Do the Eyes Have It?
    Neurology. 2022 May 26. pii: WNL.0000000000200903.
    >> Share

  105. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022;98:737-738.
    >> Share

  106. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022;98:e1818-e1827.
    >> Share

  107. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022;98:e1798-e1809.
    >> Share

    April 2022
  108. YANG JH, Graves JS
    Cancer Screening in Patients With Multiple Sclerosis: Are We Doing Enough?
    Neurology. 2022 Apr 28. pii: WNL.0000000000200366.
    >> Share

  109. HAMILTON R, Ciccarelli O
    Multiple Sclerosis Incidence in Black Patients: It's Time to Do Away With a Racial Medical Myth.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200309.
    >> Share

  110. LANGER-GOULD AM, Gonzales EG, Smith JB, Li BH, et al
    Racial and Ethnic Disparities in Multiple Sclerosis Prevalence.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200151.
    >> Share

  111. GROOME PA, Webber C, Maxwell CJ, McClintock C, et al
    Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
    Neurology. 2022 Apr 28. pii: WNL.0000000000200163.
    >> Share

  112. ROTSTEIN D, Solomon JM, Sormani MP, Montalban X, et al
    Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Neurology. 2022 Apr 26. pii: WNL.0000000000200549.
    >> Share

  113. OKAI AF, Howard AM, Williams MJ, Brink JD, et al
    Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
    Neurology. 2022 Apr 25. pii: WNL.0000000000200791.
    >> Share

  114. PORTACCIO E, Bellinvia A, Razzolini L, Pasto L, et al
    Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.
    Neurology. 2022;98:e1626-e1636.
    >> Share

  115. BEBO B, Cintina I, LaRocca N, Ritter L, et al
    Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
    Neurology. 2022 Apr 13. pii: WNL.0000000000200150.
    >> Share

  116. OSTKAMP P, Schwab N
    Effects of Latitude and Sunlight on Multiple Sclerosis Severity: Two Peas in a Pod?
    Neurology. 2022 Apr 11. pii: WNL.0000000000200105.
    >> Share

  117. VITKOVA M, Diouf I, Malpas C, Horakova D, et al
    Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study.
    Neurology. 2022 Apr 11. pii: WNL.0000000000200545.
    >> Share

  118. LEPPERT D, Kropshofer H, Haring DAA, Dahlke F, et al
    Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Neurology. 2022 Apr 4. pii: WNL.0000000000200258.
    >> Share

    March 2022
  119. BOURDETTE D, Sormani MP
    Thinking Anew: Accelerating Clinical Trials of New Therapies for Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200597.
    >> Share

  120. LI V, Leurent B, Barkhof F, Braisher M, et al
    Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 23. pii: WNL.0000000000200604.
    >> Share

  121. BRIDEL C, Killestein J, Teunissen C
    Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:471.
    >> Share

  122. KROPSHOFER H, Haring DA, Kappos L, Leppert D, et al
    Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470-471.
    >> Share

  123. LEWIS A, Galetta S
    Editors' Note: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2022;98:470.
    >> Share

  124. SIMMONS SB, Ontaneda D
    Slowly Expanding Lesions: A New Target for Progressive Multiple Sclerosis Trials?
    Neurology. 2022 Mar 11. pii: WNL.0000000000200230.
    >> Share

  125. CALVI A, Carrasco FP, Tur C, Chard DT, et al
    Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2022 Mar 11. pii: WNL.0000000000200144.
    >> Share

  126. HAMILTON RH, Ciccarelli O
    Non-White Participants Matter in White Matter Disease Studies: The Importance of Diversity in Multiple Sclerosis Clinical Trials.
    Neurology. 2022;98:345-346.
    >> Share

    February 2022
  127. LIE IA, Weeda MM, Mattiesing RM, Mol MAE, et al
    Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
    Neurology. 2022 Feb 16. pii: WNL.0000000000200006.
    >> Share

  128. MCELWEE DECKER B, Thibault D, Davis KA, Willis AW, et al
    Population-Based Study of Nonelective Postpartum Readmissions in Women With Stroke, Migraine, Multiple Sclerosis, and Myasthenia Gravis.
    Neurology. 2022 Feb 15. pii: WNL.0000000000200007.
    >> Share

  129. HACOHEN Y, Ciccarelli O
    New Evidence for EBV Infection as a Cause of Multiple Sclerosis.
    Neurology. 2022 Feb 10. pii: WNL.0000000000200243.
    >> Share

  130. TORTORELLA C, Aiello A, Gasperini C, Agrati C, et al
    Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
    Neurology. 2022;98:e541-e554.
    >> Share

    January 2022
  131. ONUORAH HM, Charron O, Meltzer E, Montague A, et al
    Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review.
    Neurology. 2022 Jan 19. pii: WNL.0000000000013230.
    >> Share

  132. CUTTER GR, Koch MW
    Multiple Sclerosis Diagnostic Criteria: Moving Ahead or Walking in Place?
    Neurology. 2022;98:12-13.
    >> Share

  133. FILIPPI M, Preziosa P, Meani A, Dalla Costa G, et al
    Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study.
    Neurology. 2022;98:e1-e14.
    >> Share

    December 2021
  134. MIRZA AI, Zhu F, Knox N, Forbes JD, et al
    Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.
    Neurology. 2021 Dec 22. pii: WNL.0000000000013245.
    >> Share

  135. SEBASTIAN P, Cherbuin N, Barcellos LF, Roalstad S, et al
    Association Between Time Spent Outdoors and Risk of Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013045.
    >> Share

  136. GRAVES JS, Killestein J
    Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis.
    Neurology. 2021 Dec 8. pii: WNL.0000000000013166.
    >> Share

    October 2021
  137. TINTORE M, Cobo-Calvo A, Carbonell P, Arrambide G, et al
    Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome.
    Neurology. 2021;97:e1641-e1652.
    >> Share

  138. AA HOGLUND RA, Meyer HE, Stigum H, Torkildsen O, et al
    Association of Body Mass Index in Adolescence and Young Adulthood and Long-term Risk of Multiple Sclerosis: A Population-Based Study.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012957.
    >> Share

  139. KALINCIK T, Tremlett H, Ascherio A
    High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.
    Neurology. 2021 Oct 25. pii: WNL.0000000000012966.
    >> Share

  140. JANDRIC D, Lipp I, Paling D, Rog D, et al
    Mechanisms of Network Changes in Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Oct 14. pii: WNL.0000000000012834.
    >> Share

  141. SIMPSON-YAP S, De Brouwer E, Kalincik T, Rijke N, et al
    Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012753.
    >> Share

  142. KILLESTEIN J, Schoonheim MM, Voskuhl RR
    B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges.
    Neurology. 2021 Oct 5. pii: WNL.0000000000012754.
    >> Share

  143. BONACCHI R, Meani A, Pagani E, Marchesi O, et al
    Association of Age at Onset With Gray Matter Volume and White Matter Microstructural Abnormalities in People With Multiple Sclerosis.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012869.
    >> Share

  144. HACOHEN Y, Eshaghi A
    Multiple Sclerosis in Children and Adults: Does Age Matter?
    Neurology. 2021 Oct 4. pii: WNL.0000000000012866.
    >> Share

  145. VRENKEN H, Jenkinson M, Pham D, Guttmann CRG, et al
    Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence.
    Neurology. 2021 Oct 4. pii: WNL.0000000000012884.
    >> Share

    September 2021
  146. MERLO D, Stankovich J, Bai C, Kalincik T, et al
    Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 23. pii: WNL.0000000000012850.
    >> Share

  147. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Colorectal Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 Sep 15. pii: WNL.0000000000012634.
    >> Share

  148. TOBIN O
    Early Diagnosis and Treatment is Associated With Improved Outcomes in Patients With Multiple Sclerosis.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012738.
    >> Share

  149. MILLER JW
    Inflammation As A Target For Epilepsy Therapy: The Case of Natalizumab.
    Neurology. 2021 Sep 14. pii: WNL.0000000000012768.
    >> Share

  150. GOLDSCHMIDT C, Fox RJ
    Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012755.
    >> Share

  151. TOBIN WO, Kalinowska-Lyszczarz A, Weigand SD, Guo Y, et al
    Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012782.
    >> Share

  152. BRIDEL C, Leurs CE, van Lierop ZY, van Kempen ZL, et al
    Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Sep 9. pii: WNL.0000000000012752.
    >> Share

  153. YEH EA, Bourdette D, Wiendl H
    Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012716.
    >> Share

  154. HAUSER SL, Kappos L, Montalban X, Craveiro L, et al
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
    Neurology. 2021 Sep 2. pii: WNL.0000000000012700.
    >> Share

  155. PALLADINO R, Chataway J, Majeed A, Marrie RA, et al
    Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality: A Population-Based Matched Cohort Study.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012610.
    >> Share

  156. SALTER A
    Assessment of Biological Interactions Between MS Status and Depression for Mortality.
    Neurology. 2021 Sep 1. pii: WNL.0000000000012615.
    >> Share

    August 2021
  157. RICE J, Xiang XM
    Comparing the Effectiveness of Therapies in People With Secondary Progressive Multiple Sclerosis.
    Neurology. 2021;97:e972-e974.
    >> Share

  158. DOBSON R, Salter A
    Differing Impact of Disease-Modifying Therapy on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
    Neurology. 2021;97:407-408.
    >> Share

  159. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    >> Share

  160. KOCH MW, Mostert J, Zhang Y, Wolinsky JS, et al
    Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
    Neurology. 2021 Aug 10. pii: WNL.0000000000012603.
    >> Share

    July 2021
  161. SECHI E, Krecke KN, Messina SA, Buciuc M, et al
    Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders.
    Neurology. 2021 Jul 14. pii: WNL.0000000000012467.
    >> Share

  162. NICHOLAS RS, Rhone EE, Mariottini A, Silber E, et al
    Autologous Haematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: a Real-world Case Series.
    Neurology. 2021 Jul 12. pii: WNL.0000000000012449.
    >> Share

  163. HACOHEN Y, Kerr W, Waters P
    Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.
    Neurology. 2021;97:12-13.
    >> Share

    June 2021
  164. GRAY-RONCAL K, Fitzgerald K, Ryerson LZ, Charvet L, et al
    Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012362.
    >> Share

  165. ROOS I, Leray E, Casey R, Horakova D, et al
    Effects of High and Low Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
    Neurology. 2021 Jun 30. pii: WNL.0000000000012354.
    >> Share

  166. HUISKAMP M, Eijlers AJC, Broeders TAA, Pasteuning J, et al
    Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis.
    Neurology. 2021 Jun 7. pii: WNL.0000000000012341.
    >> Share

  167. PREZIOSA P, Schoonheim MM
    Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In-Vivo Quantification Using Serum Neurofilament.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012331.
    >> Share

  168. CAMPBELL CREE BA, Arnold DL, Chataway J, Chitnis T, et al
    Secondary Progressive Multiple Sclerosis: New Insights.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012323.
    >> Share

  169. MAGGI P, Kuhle J, Schadelin S, van der Meer F, et al
    Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Neurology. 2021 Jun 4. pii: WNL.0000000000012326.
    >> Share

    May 2021
  170. ROLLOT F, Fauvernier M, Uhry Z, Vukusic S, et al
    Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort.
    Neurology. 2021 May 19. pii: WNL.0000000000012224.
    >> Share

  171. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Breast Cancer Survival in Multiple Sclerosis: A Matched Cohort Study.
    Neurology. 2021 May 19. pii: WNL.0000000000012127.
    >> Share

  172. TOOSY AT, Kapur K, Nair KV
    Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?
    Neurology. 2021;96:927-928.
    >> Share


  173. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 May 4. pii: WNL.0000000000011825.
    >> Share

  174. FOX RJ, Kryscio RJ
    A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis.
    Neurology. 2021;96:833-834.
    >> Share

  175. KOCH MW, Sage K, Kaur S, Kim J, et al
    Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Neurology. 2021;96:e2313-e2322.
    >> Share

  176. BAR-OR A, Herman A, Stokmaier D
    Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  177. HAHN N
    Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:870.
    >> Share

  178. SIEGLER JE, Galetta S
    Editors' Note: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
    Neurology. 2021;96:869.
    >> Share

    April 2021
  179. DUBESSY AL, Tezenas du Montcel S, Viala F, Assouad R, et al
    Association of Central Hypersomnia and Fatigue in Patients With Multiple Sclerosis: A Polysomnographic Study.
    Neurology. 2021 Apr 30. pii: WNL.0000000000012120.
    >> Share

  180. LEAVITT VM, Dobson R, Svennigsson A
    Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.
    Neurology. 2021 Apr 28. pii: WNL.0000000000012101.
    >> Share

  181. SALAVISA M, Serrazina F, Pires P, Correia AS, et al
    Teaching Video NeuroImages: Infratentorial Multiple Sclerosis Relapse Presenting as Continuous Hemifacial Myokymia.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012052.
    >> Share

  182. GASPERI C, Hapfelmeier A, Daltrozzo T, Schneider A, et al
    Systematic Assessment of Medical Diagnoses Preceding the First Diagnosis of Multiple Sclerosis.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012074.
    >> Share

  183. SOLOMON AJ, Ascherio A
    Early Diagnosis of Multiple Sclerosis: Further Evidence for Missed Opportunity.
    Neurology. 2021 Apr 26. pii: WNL.0000000000012087.
    >> Share


  184. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Apr 23. pii: WNL.0000000000012021.
    >> Share

  185. EID K, Torkildsen OF, Aarseth J, Flemmen HO, et al
    Perinatal Depression and Anxiety in Women with Multiple Sclerosis: A Population-Based Cohort Study.
    Neurology. 2021 Apr 21. pii: WNL.0000000000012062.
    >> Share

  186. YEH WZ, Widyastuti PA, Van der Walt A, Stankovich J, et al
    Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Neurology. 2021 Apr 20. pii: WNL.0000000000012084.
    >> Share

  187. LAMBE J, Risher H, Filippatou AG, Murphy OC, et al
    Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Neurology. 2021 Apr 7. pii: WNL.0000000000011933.
    >> Share

    March 2021
  188. POIRION E, Tonietto M, Lejeune FX, Ricigliano VAG, et al
    Structural and Clinical Correlates of a Periventricular Gradient of Neuroinflammation in Multiple Sclerosis.
    Neurology. 2021 Mar 18. pii: WNL.0000000000011700.
    >> Share

  189. LAMBE J, Fitzgerald KC, Murphy OC, Filippatou AG, et al
    Association of Spectral-Domain OCT With Long-term Disability Worsening in Multiple Sclerosis.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011788.
    >> Share

  190. VILLOSLADA P, Galetta SL, Toosy A
    Seeing the Finish Line: Can Baseline OCT Values Predict Long-Term Disability and Therapeutic Management in Multiple Sclerosis?
    Neurology. 2021 Mar 2. pii: WNL.0000000000011793.
    >> Share

  191. BANSAL P, Paul BS, Singh G
    Multiple Sclerosis Relapse Presenting As Sensorineural Hearing Loss.
    Neurology. 2021 Mar 2. pii: WNL.0000000000011796.
    >> Share

    February 2021
  192. KALAITZIDIS G, Calabresi PA
    Is Cerebrospinal Fluid Responsible for Innate Immune Cell Activation and Neurotoxicity in Multiple Sclerosis?
    Neurology. 2021 Feb 15. pii: WNL.0000000000011694.
    >> Share


  193. Evaluation of Multiple Sclerosis Disability Outcome Measures Using Pooled Clinical Trial Data.
    Neurology. 2021 Feb 12. pii: WNL.0000000000011677.
    >> Share

    January 2021
  194. ALPING P, Burman J, Lycke J, Frisell T, et al
    Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Non-induction Therapies for Multiple Sclerosis.
    Neurology. 2021 Jan 29. pii: WNL.0000000000011545.
    >> Share

  195. BROWNLEE WJ, Galetta S
    Optic Nerve in Multiple Sclerosis Diagnostic Criteria: An Aye to the Eyes?
    Neurology. 2021;96:139-140.
    >> Share

  196. SORMANI MP, Tur C, Barkhof F
    Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?
    Neurology. 2021;96:141-142.
    >> Share

  197. BOFFA G, Massacesi L, Inglese M, Mariottini A, et al
    Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Neurology. 2021 Jan 20. pii: WNL.0000000000011461.
    >> Share

  198. LEAVITT VM, Rocca M
    Siponimod for Cognition in Secondary Progressive Multiple Sclerosis: Thinking Through the Evidence.
    Neurology. 2021;96:91-92.
    >> Share

  199. ROCCA MA, Valsasina P, Meani A, Gobbi C, et al
    Association of Gray Matter Atrophy Patterns with Clinical Phenotype and Progression in Multiple Sclerosis.
    Neurology. 2021 Jan 13. pii: WNL.0000000000011494.
    >> Share

  200. BOVIS F, Kalincik T, Lublin F, Cutter G, et al
    Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
    Neurology. 2021;96:e214-e227.
    >> Share

  201. SHAH S, Klassen BT, Flanagan EP
    Paroxysmal Dysarthria-Ataxia in Multiple Sclerosis.
    Neurology. 2021 Jan 5. pii: WNL.0000000000011498.
    >> Share

  202. KALINCIK T, Sormani MP, Tur C
    Has the Time Come to Revisit Our Standard Measures of Disability Progression in Multiple Sclerosis?
    Neurology. 2021;96:12-13.
    >> Share

    December 2020
  203. KALINCIK T, Diouf I, Sharmin S, Malpas C, et al
    Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
    Neurology. 2020 Dec 28. pii: WNL.0000000000011242.
    >> Share


  204. The 2013 clinical course descriptors for multiple sclerosis: A clarification.
    Neurology. 2020 Dec 22. pii: WNL.0000000000011198.
    >> Share

  205. BENEDICT RHB, Tomic D, Cree BA, Fox R, et al
    Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011275.
    >> Share

  206. VIDAL-JORDANA A, Rovira A, Arrambide G, Otero-Romero S, et al
    Optic nerve region in multiple sclerosis diagnosis: the utility of visual evoked potentials.
    Neurology. 2020 Dec 16. pii: WNL.0000000000011339.
    >> Share

  207. NAISMITH RT, Bermel RA, Coffey CS, Goodman AD, et al
    Effects of ibudilast on MRI measures in the phase 2 SPRINT-MS study.
    Neurology. 2020 Dec 2. pii: WNL.0000000000011314.
    >> Share

  208. LANGESKOV-CHRISTENSEN M, Grondahl Hvid L, Nygaard MKE, Ringgaard S, et al
    Efficacy of high-intensity aerobic exercise on brain MRI measures in multiple sclerosis.
    Neurology. 2020 Dec 1. pii: WNL.0000000000011241.
    >> Share

  209. BINZER S, Manouchehrinia A, Hillert J
    Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1026.
    >> Share

  210. BSTEH G, Berger T
    Reader response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025-1026.
    >> Share

  211. GANESH A, Galetta S
    Editors' note: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study.
    Neurology. 2020;95:1025.
    >> Share

    November 2020
  212. MARRIE RA, Maxwell C, Mahar A, Ekuma O, et al
    Cancer incidence and mortality rates in multiple sclerosis: A matched cohort study.
    Neurology. 2020 Nov 25. pii: WNL.0000000000011219.
    >> Share

    October 2020
  213. KOCH MW, Mostert J, Repovic P, Bowen JD, et al
    Reliability of outcome measures in clinical trials in secondary progressive multiple sclerosis.
    Neurology. 2020 Oct 26. pii: WNL.0000000000011123.
    >> Share

  214. KLEIN DA COSTA B, Brant de Souza Melo R, Passos GRD, Gomes Meneses Sevilha Castro D, et al
    Unraveling B lymphocytes in CNS inflammatory diseases: Distinct mechanisms and treatment targets.
    Neurology. 2020;95:733-744.
    >> Share

    September 2020
  215. ROTSTEIN DL, Yeh EA
    Could wider social networks prevent disability in MS and other neurologic disorders?
    Neurology. 2020;95:463-464.
    >> Share

    August 2020
  216. WALLIN MT
    Initial highly effective therapy for MS: A strong start.
    Neurology. 2020;95:e1114-e1116.
    >> Share

  217. OUTTERYCK O, Lopes R, Drumez E, Labreuche J, et al
    Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome.
    Neurology. 2020;95:e733-e744.
    >> Share

  218. VAN KEMPEN ZLE, Hoogervorst ELJ, Wattjes MP, Kalkers NF, et al
    Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    Neurology. 2020;95:e745-e754.
    >> Share

  219. DIXON L, Shah S
    Teaching NeuroImages: Hypertrophic polyneuropathy.
    Neurology. 2020;95:e779-e780.
    >> Share

  220. NELSON LM, Bourdette D
    Two decades of research: Time to incorporate comorbidity management into the care of MS?
    Neurology. 2020;95:193-194.
    >> Share

  221. SALTER A, Kowalec K, Fitzgerald KC, Cutter G, et al
    Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.
    Neurology. 2020;95:e446-e456.
    >> Share

    July 2020
  222. KILLESTEIN J, Du Pasquier R, Hemmer B
    Vaccination in B-cell depleted MS patients.
    Neurology. 2020 Jul 29. pii: WNL.0000000000010378.
    >> Share

  223. CHEN JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, et al
    Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder.
    Neurology. 2020;95:e111-e120.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016